Investigational Drug Information for Idalopirdine
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Idalopirdine?
Idalopirdine is an investigational drug.
There have been 10 clinical trials for Idalopirdine.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 7th 2014.
The most common disease conditions in clinical trials are Alzheimer Disease and [disabled in preview]. The leading clinical trial sponsors are H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., and [disabled in preview].
There are twenty-nine US patents protecting this investigational drug and five hundred and fifty-two international patents.
Summary for Idalopirdine
| US Patents | 29 |
| International Patents | 552 |
| US Patent Applications | 92 |
| WIPO Patent Applications | 60 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 3 (2014-04-07) |
| Vendors | 48 |
Recent Clinical Trials for Idalopirdine
| Title | Sponsor | Phase |
|---|---|---|
| Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease | H. Lundbeck A/S | Phase 1 |
| Bioequivalence Study of Idalopirdine in Healthy Subjects | H. Lundbeck A/S | Phase 1 |
| Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men | H. Lundbeck A/S | Phase 1 |
Clinical Trial Summary for Idalopirdine
Top disease conditions for Idalopirdine
Top clinical trial sponsors for Idalopirdine
US Patents for Idalopirdine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Idalopirdine | See Plans and Pricing | Polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzyla- mine hydrochloride for the treatment of Alzheimer's disease | H. LUNDBECK A/S (Valby, DK) | See Plans and Pricing |
| Idalopirdine | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Idalopirdine | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Idalopirdine | See Plans and Pricing | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Idalopirdine | See Plans and Pricing | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in Parkinson's disease patients | H. LUNDBECK A/S (Valby, DK) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Idalopirdine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Idalopirdine | Argentina | AR101109 | 2034-07-04 | See Plans and Pricing |
| Idalopirdine | Australia | AU2015282909 | 2034-07-04 | See Plans and Pricing |
| Idalopirdine | Brazil | BR112017000127 | 2034-07-04 | See Plans and Pricing |
| Idalopirdine | Canada | CA2951794 | 2034-07-04 | See Plans and Pricing |
| Idalopirdine | Chile | CL2017000002 | 2034-07-04 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
